These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35558920)

  • 41. Drug Design Concepts for LSD1-Selective Inhibitors.
    Ota Y; Suzuki T
    Chem Rec; 2018 Dec; 18(12):1782-1791. PubMed ID: 30277644
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel Tranylcypromine/Hydroxylcinnamic Acid Hybrids as Lysine-Specific Demethylase 1 Inhibitors with Potent Antitumor Activity.
    Han Y; Wu C; Lv H; Liu N; Deng H
    Chem Pharm Bull (Tokyo); 2015; 63(11):882-9. PubMed ID: 26521853
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies.
    Valente S; Rodriguez V; Mercurio C; Vianello P; Saponara B; Cirilli R; Ciossani G; Labella D; Marrocco B; Ruoppolo G; Botrugno OA; Dessanti P; Minucci S; Mattevi A; Varasi M; Mai A
    ACS Med Chem Lett; 2015 Feb; 6(2):173-7. PubMed ID: 25699146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells.
    Huang Y; Vasilatos SN; Boric L; Shaw PG; Davidson NE
    Breast Cancer Res Treat; 2012 Feb; 131(3):777-89. PubMed ID: 21452019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression.
    Chen L; Vasilatos SN; Qin Y; Katz TA; Cao C; Wu H; Tasdemir N; Levine KM; Oesterreich S; Davidson NE; Huang Y
    Oncotarget; 2017 Oct; 8(47):81737-81753. PubMed ID: 29137219
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
    Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
    Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors.
    Ma L; Wang H; You Y; Ma C; Liu Y; Yang F; Zheng Y; Liu H
    Acta Pharm Sin B; 2020 Sep; 10(9):1658-1668. PubMed ID: 33088686
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimization of 5-arylidene barbiturates as potent, selective, reversible LSD1 inhibitors for the treatment of acute promyelocytic leukemia.
    Xu S; Zhou C; Liu R; Zhu Q; Xu Y; Lan F; Zha X
    Bioorg Med Chem; 2018 Sep; 26(17):4871-4880. PubMed ID: 30153955
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A.
    Mimasu S; Sengoku T; Fukuzawa S; Umehara T; Yokoyama S
    Biochem Biophys Res Commun; 2008 Feb; 366(1):15-22. PubMed ID: 18039463
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
    Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
    Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
    Murray-Stewart T; Woster PM; Casero RA
    Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
    Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
    Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and biological evaluation of novel (E)-N'-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors.
    Zhou Y; Li Y; Wang WJ; Xiang P; Luo XM; Yang L; Yang SY; Zhao YL
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4552-4557. PubMed ID: 27524309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and crystallographic evaluation of histone H3 peptide with N-terminal serine substitution as a potent inhibitor of lysine-specific demethylase 1.
    Amano Y; Kikuchi M; Sato S; Yokoyama S; Umehara T; Umezawa N; Higuchi T
    Bioorg Med Chem; 2017 May; 25(9):2617-2624. PubMed ID: 28336409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells.
    Liu S; Lu W; Li S; Li S; Liu J; Xing Y; Zhang S; Zhou JZ; Xing H; Xu Y; Rao Q; Deng C; Wang M; Wang J
    Oncotarget; 2017 May; 8(19):31901-31914. PubMed ID: 28404874
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
    Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
    Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
    Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
    J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Xanthoangelol and 4-Hydroxyderricin Are the Major Active Principles of the Inhibitory Activities against Monoamine Oxidases on Angelica keiskei K.
    Kim JH; Son YK; Kim GH; Hwang KH
    Biomol Ther (Seoul); 2013 May; 21(3):234-40. PubMed ID: 24265870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design, synthesis and biological evaluation of curcumin analogues as novel LSD1 inhibitors.
    Wang J; Zhang X; Yan J; Li W; Jiang Q; Wang X; Zhao D; Cheng M
    Bioorg Med Chem Lett; 2019 Dec; 29(23):126683. PubMed ID: 31627991
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors.
    Wang S; Zhao LJ; Zheng YC; Shen DD; Miao EF; Qiao XP; Zhao LJ; Liu Y; Huang R; Yu B; Liu HM
    Eur J Med Chem; 2017 Jan; 125():940-951. PubMed ID: 27769034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.